Mainz Biomed insider buys 643,850 shares

Mainz Biomed N.V. insider Donahue Kevin Michael, identified as a 10% owner, reported buying common stock.

Rhea-AI Filing Summary

Mainz Biomed N.V. insider Donahue Kevin Michael, identified as a 10% owner, reported buying common stock. On 10/17/2025, he acquired 643,850 shares of Mainz Biomed common stock in a single open-market or private purchase transaction reported with code "P." Following this transaction, his directly held beneficial ownership stands at 643,850 shares.

Insights

Equity ownership and insider-transactions analyst

Large direct share purchase by a 10% owner is disclosed.

The filing shows that 10% owner Donahue Kevin Michael purchased 643,850 shares of Mainz Biomed N.V. common stock on 10/17/2025. The transaction is coded "P," which indicates a purchase of non-derivative securities. After this trade, he directly owns 643,850 shares of the company.

This is a sizeable single reported transaction by a large shareholder, but there is no context here about total shares outstanding, prior ownership, or pricing relative to market levels. Without those details, the long‑term significance for valuation or control is hard to gauge, and any impact will depend on how this ownership position fits into the broader shareholder base as described in other company disclosures.

Insider Trade Summary

Net Buyer: 643,850 shares

Net Buy 1 txn

Insider Donahue Kevin Michael

Role 10% Owner

Bought 643,850 shs

Type	Security	Shares	Price	Value
Purchase	Common Stock	643,850	$402,000.00 as filed	--

• Price shown as filed: $402,000.00 per share is far above the $1.49 close on Oct 17, 2025, so no transaction value is shown.

Holdings After Transaction: Common Stock — 643,850 shares (Direct)

FAQ

Who reported the insider transaction in Mainz Biomed (MYNZ)?

The transaction was reported by Donahue Kevin Michael, who is listed as a 10% owner of Mainz Biomed N.V.

What type of security did the Mainz Biomed (MYNZ) insider buy?

The insider purchased Common Stock of Mainz Biomed N.V..

How many Mainz Biomed (MYNZ) shares were purchased in this Form 4?

The Form 4 reports a purchase of 643,850 shares of Mainz Biomed common stock in a single transaction.

What is the insider’s total share ownership in Mainz Biomed (MYNZ) after the transaction?

Following the reported purchase, the filing shows 643,850 shares of Mainz Biomed common stock beneficially owned directly by the reporting person.

Was this Mainz Biomed (MYNZ) insider transaction in derivative securities?

No. The reported transaction involves non-derivative securities (common stock), and the table for derivative securities shows no entries.

What is the transaction code used in this Mainz Biomed (MYNZ) Form 4?

The transaction is labeled with code "P", indicating a purchase of non-derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/16/2026 - 03:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donahue Kevin Michael

(Last) (First) (Middle)

2502 KIRBY STREET

(Street)

DALLAS TX 75204

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAINZ BIOMED N.V. [ MYNZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/17/2025		P		643,850	A	$402,000	643,850	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Kevin Donahue	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.